Techniques for detecting real-time proton beam dose include retrieving conversion data for converting proton dose to acoustic pressure based on medical imagery. 3D medical imagery is retrieved of a first region of interest (ROI) inside a first subject. A real-time signal indicates ultrasound pressure at a 2D ultrasound array disposed outside and in contact with the first subject close to the first ROI. Real-time 3D dose delivered in the first ROI is determined by inputting the real-time signal into a dose detection module that includes a neural network. The neural network is trained on multiple instances of a training set. Each instance includes: simulated proton dose delivered to a similar ROI inside a second subject; simulated pressure generation from that simulated dose based on the conversion data and a similar 3D medical image; and simulated acoustic transmission from the similar ROI to a similar two-dimensional ultrasound transducer array similarly disposed.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
2.
SELECTIVE MULTIPLEXED ELECTROCHEMICAL PLATFORM FOR DETECTION OF HIV INFECTION
The present application provides a multiplex detecting platform for diagnosing HIV infection in a subject, as well as methods for diagnosing HIV infection with the multiplex detecting platform described herein.
An implantable device for sacroiliac (“SI”) joint fusion and an associated method employ an SI joint fusion portion and an anchor portion of smaller diameter than the SI joint fusion portion and that extends distally from a distal end of the SI joint fusion portion. The SI joint fusion portion is externally threaded and is configured to, when surgically implanted, extend across the SI joint. The anchor portion in turn extends distally from the SI joint fusion portion and is configured for implanting entirely within the patient's ilium adjacent the SI joint. In certain configurations, the joint fusion portion is configured to enable fixation of spinal equipment at a proximal end of the joint fusion portion. A stabilizing driver is additionally provided to aid in placement of the device when obstructions are present.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Fulton, Amy M.
Weber, David J.
Godoy-Ruiz, Raquel
Kundu, Namita
Abstract
Colocasia esculentaColocasia esculenta. This protein has been found to have potent anti-metastatic activity against an aggressive malignancy and a higher specific activity than the prior art taro storage protein composition. The invention therefore relates to the protein compositions described herein, pharmaceutical compositions comprising the recombinant proteins, and to methods for treating cancer, for example breast cancer, using the recombinant proteins or pharmaceutical compositions comprising the recombinant proteins.
5.
PH-SENSITIVE ANTI-CTLA-4 ANTIBODIES AND USES THEREOF
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
An MR-compatible frame is configured for use in Magnetic Resonance (MR) guided focused ultrasound (MRgFUS) procedures. The frame is constructed from non-magnetic materials to ensure compatibility with MRI environments and to avoid interference with imaging quality and patient safety. The frame includes a hinge mechanism that allows for transitioning of the frame between open and closed states to enable quick and comfortable setup and removal around a patient's head. Adjustable components, including an adjustable back rest and adjustable, swivel-mounted front cushions enable customization to fit various head sizes and shapes to ensure a secure and stable positioning of the patient's head during procedures.
Systems and methods for optimizing encoding, communicating, decoding, or a combination thereof of graphical data are provided. A training data set including first graphical data defined by a sampling resolution and first modality are obtained. A trained feature extraction model and performance data are obtained. Second graphical data is encoded forming an encoded byte stream including a plurality of sequence scans. Each scan is associated with a unique rank order defining a sequence and a corresponding progressive resolution that is based on a resolution of a preceding scan or a predetermined resolution. A first training resolution is matched to the desired threshold performance. The encoded byte stream and instructions to terminate decoding of the encoded byte stream at the second computer system when the decoding decodes a sequence scan in the plurality of sequence scans that matches or exceeds the first training resolution are communicated.
Engineered cells that serve as vehicles to deliver genetically-encoded cargo molecules, such as therapeutic molecules, to other cells in vivo are provided. In particular, fusogenic biovesicles with reduced immunogenicity potential, expressing poorly immunogenic (fully human or humanised or deimmunised) fusogens enclosing the cargo molecules are produced by the engineered cells. The engineered cells can be used in methods of treating diseases and conditions such as amyotrophic lateral sclerosis, Alzheimer's disease and cancer.
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
9.
Methods of Improving Recovery After Lung Resection
Mayo Foundation for Medical Education and Research (USA)
Inventor
Krupnick, Alexander Sasha
Mei, Zhongcheng
Jacobsen, Elizabeth
Abstract
Provided herein are methods for inhibiting or preventing activation of eosinophil production in a subject after a pulmonary surgical or medical procedure. Therapeutic, inhibitory or targeting agents administered to the subject are effective to inhibit the eosinophil activation pathway in the lungs. The therapeutic, inhibitory or targeting agents may be a monoclonal antibody or engineered antibody, a chemical compound, a protein or a fusion protein. The agents are effective to inhibit cytokines, receptors or proteins and enzymes associated with eosinophil production.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
10.
METHODS OF PREDICTING LONG-TERM OUTCOME IN KIDNEY TRANSPLANT PATIENTS USING PRE-TRANSPLANTATION KIDNEY TRANSCRIPTOMES
The first genome-wide, large-cohort study to demonstrate donor kidney transcriptomes can capture intrinsic organ quality and carry significant predictive weight for 24-month transplant function is disclosed. These findings shift the paradigm of understanding longer-term kidney transplant outcomes away from recipient factors/post-transplant events and towards intrinsic donor organ quality, which can be captured by molecular techniques. The combined predictive equation provided herein, using both clinical and biological data, can more accurately predict 24-month outcomes as compared to the current established scoring system (KDPI) in an external patient cohort.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention discloses a self-sealing cannula and methods of its use. The self-sealing cannula can be minimally invasively placed into the heart for drawing and/or returning blood with a self-sealing function at the interface of the blood access site. The disclosed cannula can be implemented as a single lumen cannula or a double lumen cannula, which can be used with ventricular assist devices for heart support or pump-oxygenators for ECMO and respiratory support. Through a self-sealing mechanism fixed on the ventricular wall or atrial wall, a cannula body is attached to the self-sealing fixture and blood is drawn into the lumen via an external pump and returned to the circulation system through a separate cannula. In the case of the double lumen cannula embodiment, the blood will be drawn into the drainage lumen of the double lumen cannula and returned through an infusion lumen at the desired location. The present invention achieves minimally invasive insertion without surgical sutures to the heart, and allows for optimal drainage of the blood from the heart. With use of the double lumen cannula, it prevents need for multiple cannulation sites, and greatly reduces the blood recirculation. Removal of the cannula is simplified without need for suturing or insertion of a plugging member.
A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
The invention relates to small molecule inhibitors of GPR68, useful as therapeutic agents in conditions benefitted from inhibition of GPR68, such as cancers and acute lung injuries. Selective inhibition of GPR68 caused robust cell death in glioblastoma cell lines, without toxicity, as well as death of other cancer cells, such as lung and pancreatic cancers. Synergistic benefits are achieved using combination treatment of GPR68 inhibitor compounds with radiation therapy or traditional chemotherapies for cancers. Thus, GPR68 inhibition enhances the therapeutic efficacy of ionizing radiation and chemotherapies. GPR68 inhibition is a therapeutic approach to induce ferroptosis in glioblastoma multiforme and other cancers, in a synergistic manner with ionizing radiation. Since ferroptosis is a form of immunogenic cell death, GPR68 inhibition represents an attractive approach to enhance cancer immunotherapies, including check-point inhibitors and cancer vaccines. The treatment methods also show beneficial results in acute lung injury such as acute respiratory distress syndrome.
C07D 285/14 - Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
UNIVERSITY OF MARYLAND MEDICAL SYSTEM CORPORATION (USA)
Inventor
Griffith, Bartley
Wu, Zhongjun
Shah, Aakash
Smith, Ryan
Abstract
A method and system provide an end-to-side anastomosis graft via percutaneous access for cardiac and vascular surgeries. The system includes a vascular graft configured for stable placement within a vessel, a sheath for long-term maintenance and use of the graft, and a closure device configured for secure ligation and transection of the graft when no longer in use. The system facilitates the use of extracorporeal life support devices and other cardiac interventions, reducing the need for open surgical exposure and allowing use by non-surgeons, such as interventional cardiologists.
A61B 17/12 - Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61F 2/90 - Stents in a form characterised by wire-like elements; Stents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
A61B 17/11 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for performing anastomosis; Buttons for anastomosis
15.
PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF
Proteolysis-targeting chimeras (PROTACs) and chimeric compounds that inhibit B-Cell Lymphoma-2 (Bcl-2) protein, and methods of using the same, are provided for treating disease.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 35/02 - Antineoplastic agents specific for leukemia
16.
UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER
The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
Provided herein are fusion proteins engineered from a dysferlin C2 domain sequence linked to a sequence of a homologous fusion partner, vector constructs with cDNA encoding the fusion proteins and viral vectors with the vector constructs and a promoter to control expression thereof. Also provided are methods for treating a dysferlinopathy in a subject in need thereof, for suppressing pathogenic Ca2+ signaling in a dysferlinopathic muscle and for targeting proteins to triad junctions in skeletal muscles all utilizing at least the fusion proteins.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
Provided herein are dental adhesives that contain a dental adhesive material and a multifunctional magnetic platform. The multifunctional magnetic platform has a core-shell structure. The core includes magnetic microparticles and an antibiotic with the core capped by an antibacterial silane coating. Also provided are methods utilizing the dental adhesives for increasing longevity of a dental restoration and for restoring a tooth in a subject.
Proteolysis-targeting chimeras (PROTACs) that indirectly inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 35/02 - Antineoplastic agents specific for leukemia
20.
METHODS OF TREATING SEPSIS USING POLY(LACTIC ACID) NANOPARTICLES
Methods of treating sepsis via administration of poly(lactic acid) (PLA) immunomodulatory nanoparticles (iNPs) are disclosed. Such methods can also be used to modulate an immune response in a subject having sepsis and promote an anti-inflammatory response in such subjects.
Methods for preventing neural tube defects in embryos of diabetic females via administration of Survivin-containing exosomes derived from Flk-1+ mesoderm progenitor cells are reported.
A fluorescence-based analytical platform comprising methods, software and instrumentation that accomplishes direct, rapid, high throughput, multiplex, and quantitative determinations of virion populations, in human or animals or experimental fluids, that are impacted by, or escape from, interactions with antiviral drugs. The platform can be used to advance bnAb resistance detection capacities to support numerous bnAb clinical trial activities, from screening volunteers to tailoring subject-specific bnAb combinations for treatment or cure.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
23.
DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE
Compounds and compositions are provided as inhibitors of the Wnt/beta-catenin pathway and/or activators of the adenosine monophosphate-activated kinase (AMPK) pathway for the treatment of diseases that implicate the same. Such diseases include cancer or a metabolic disease. Cancers that may be treated by these compounds and compositions include adrenocortical cancer, hepatocellular cancer, hepatoblastoma, malignant melanoma, ovarian cancer, Wilm's tumor, Barrett's esophageal cancer, prostate cancer, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, bladder cancer, breast cancer (e.g. triple negative breast cancer), gastric cancer, head & neck cancer, lung cancer, mesothelioma, cervical cancer, uterine cancer, myeloid leukemia cancer, lymphoid leukemia cancer, pilometricoma cancer, medulloblastoma cancer, glioblastoma, and familial adenomatous polyposis. Metabolic diseases include type 2 diabetes, obesity, hyperlipidemia, alcoholic or non-alcoholic fatty liver disease, and liver fibrosis.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The device of the present invention includes an integrated multi-chamber gas exchanger/oxygenator that is configured for increased flexibility, scalability, and mobility for various clinical applications, such as in an extracorporeal membrane oxygenation (ECMO) circuitry, in a heartlung machine for cardiopulmonary support during cardiothoracic surgery, and as a temporary respiratory assist device for patients with lung failure. The gas exchanger features two sweep gas flow paths and two consecutive hollow fiber membrane bundles enclosed in a housing structure with multiple blood flow and sweep gas distribution mechanisms and various combinations of blood flow paths through the two hollow fiber membrane bundles. The multi-chamber gas exchanger provides improved flexibility in geometries and blood flow patterns of the two hollow fiber membrane bundles and eases manufacturing complications. The multi-chamber gas exchanger includes an outer housing, an intermediate blood connector between the two hollow fiber membrane bundles, two gas exchange hollow fiber membrane bundles, a blood inlet, a blood outlet, a gas inlet for each hollow fiber membrane bundle, and gas outlets for the two hollow fiber membrane bundles.
Disclosed are compositions comprising a fusion polypeptide comprising i) a fusion of a needle tip protein or an antigenic fragment thereof and/or a translocator protein or an antigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria and ii) the A1 subunit of the labile toxin (LTA1) from enterotoxigenic Escherichia coli or cholera toxin, and methods of their use.
C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
C07K 14/21 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
C07K 14/235 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
C07K 14/24 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
C07K 14/28 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
26.
METHODS AND PLATFORMS FOR PROMOTING ANTIGEN-SPECIFIC TOLERANCE IN THE TREATMENT OF TYPE 1 DIABETES AND GRAFT REJECTION AND COMPOSITIONS RELATING THERETO
The present disclosure is directed to systems, compositions and methods for promoting immune tolerance to an antigen in a subject. Systems and methods provide for introducing directly into at least one lymph node(s) of the subject a therapeutically effective amount of a composition comprising an antigen associated with an autoimmune disease or disorder, in combination with a carrier comprising an immune modulatory agent such that an immune response to said antigen is inhibited or suppressed in the subject. The present disclosure is also directed to systems, compositions and methods for the treatment and/or prevention of autoimmune diseases and conditions, and in particular type 1 diabetes and graft rejection.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
27.
ENGINEERED ANTI-NOCICEPTIVE-LOS COMPETITIVE TLR4 LIGANDS AND METHODS FOR TREATING PAIN WHILE MAINTAINING IMMUNOSUFFICIENCY
The present invention provides anti-pain lipid A based therapeutic compounds, compositions comprising the same and methods of treating pain by administering effective amounts of the same to subjects in need of treatment.
Described herein are devices and methods for mitral valve repair. The devices and methods implant a plurality of distal anchors at an annulus of the mitral valve (e.g., the posterior annulus) and tension artificial chordae to pull the portion of the annulus toward an opposite edge and inward into the ventricle. This can effectively reduce the size of the orifice and increase coaptation. The delivery devices can be configured to be actuated to form a distal anchor made of a pre-formed knot. The delivery devices deliver the pre-formed knot in an elongate configuration. Actuation of the delivery device causes the pre-formed knot to transition from the elongate configuration to the deployed configuration by approximating opposite ends of a suture coupled to a coiled configuration to form one or more loops. After formation of the knot, the delivery device can be withdrawn.
The present invention provides methods of detecting the presence or absence of nucleic acid from Chlamydia trachomatis and the presence or absence of nucleic acid from Neisseria gonorrhoeae in a sample from a subject using CRISPR nucleases and crRNAs specific for Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid, kits for carrying out the methods and methods of treating subjects infected with Chlamydia trachomatis and/or Neisseria gonorrhoeae.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 207/416 - 2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
32.
METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS
Provided herein are compositions relating to psychedelics and serotonin receptor modulators. Further provided herein are methods of treating a disease or disorder (e.g., depression or diseases or disorders related to depression) comprising administering psychedelics and serotonin receptor modulators.
The present invention provides an improved percutaneous dilation tracheostomy device. The device is configured to include all of the required components to perform a percutaneous tracheotomy. The device includes a retractable needle and an extendable j-wire rather than having separate components as in typical percutaneous tracheostomy devices. The device includes a dilator section to expand the diameter of a patient's stoma. The device is further configured to allow an operator to perform a bubble test to alert the user that the tube is in the trachea. In addition, the device is generally more compact than typical emergency tracheostomy devices.
The use of a cell-permeant molecular probe to assay the presence, and monitor the production, of the reactive oxygen species, superoxide, in red blood cells (RBCs) is described. The assay is performed using electron paramagnetic resonance (EPR) spectroscopy and a cell-permeant hydroxylamine spin trap. The cell-permeant molecular probe is not detected or quantifiable by EPR in its reduced form. However, upon entering the RBCs, the probe is oxidized by reacting with superoxide to yield a stable nitroxide radical that is detected and quantified using EPR. Our studies indicate that superoxide production is consistent with RBC metabolism that predicts lipid oxidation, membrane injury and poor post-transfusion performance. Therefore, measurement of reactive oxygen species can be used as an indicator of RBC quality at the time of donation and after storage.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
36.
GALLIUM-SALOPHEN ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic System
37.
BOVINE COLOSTRUM-DERIVED NUTRITIONAL SUPPLEMENTS AND USES THEREOF
Provided herein are nutritional supplements of a plurality of metabolite compounds effective as anti-inflammatories in an animal gut for an animal feed and the animal feed and animal food products containing the same and nutritional supplements formulated as a mix¬ ture of gut-associated metabolites. Also provided are methods for increasing growth of a food animal or a farm animal, improving a gut microenvironment in an animal and increasing an anti-inflammatory response in an animal that utilize the supplemented animal feed and animal food products and a method for improving gut health in an animal that is administered or takes the nutritional supplement formulation.
We disclose here the nano-enabled delivery of highly potent 5 -hydroxymethyl furfural (5-HMF) to sickled blood cells in patients. 5-HMF, a superior antisickling agent, has been formulated to address the limitations of existing treatment modalities arising from disfavorable pharmacokinetics of the drug compound. Specifically, two complementary 5-HMF prodrugs are integrated as a "protected" biocompatible composite nanoparticle designed to readily fuse with RBCs and be amenable to transdermal delivery (5-HMF-grafted-phospholipid layered over a sucrose-derived graphitic carbon dot core). These RBC-targeted, protected, biocompatible, self-assembled 5-HMF prodrug nanoparticles for sickle cell disease are the first in class technology for offering a treatment for sickle cell disease which has improved potency, targeted payload delivery, and extended release with the red blood cells with enhanced pharmacodynamic effect in a treated patient.
C07D 307/34 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A tissue anchor includes an elongate tube including a distal tubular portion, a medial tubular portion, a proximal tubular portion, a distal radially-expandable portion positioned between the distal tubular portion and the medial tubular portion, and a proximal radially-expandable portion positioned between the medial tubular portion and the proximal tubular portion. The tissue anchor further includes a suture disposed within a lumen of the elongate tube and passing axially through the distal tubular portion, the distal radially-expandable portion, the medial tubular portion, the proximal radially-expandable portion, and the proximal tubular portion. Longitudinal slits can be implemented to facilitate radial expansion of the proximal and distal radially-expandable portions of the tube.
A61B 17/04 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for suturing wounds; Holders or packages for needles or suture materials
40.
LIVE SALMONELLA TYPHI VECTORS ENGINEERED TO EXPRESS HETEROLOGOUS OUTER MEMBRANE PROTEIN ANTIGENS AND METHODS OF USE THEREOF
The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
42.
SALTS OF GALETERONE AND SALTS OF NEXT GENERATION GALETERONE ANALOGS, AND USES THEREOF
A salt of 3β-(hydroxy)-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (Compound 1) or a salt of 3β-(1H-imidazole-1-yl-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (Compound 2), wherein the salt is at least one selected from the group consisting of a hydrochloride, a dihydrochloride, a sodium, a tosylate, a mesylate, a succinate, a sulfate, a disulfate, a maleate, a fumarate, a phosphate, and a diphosphate salt; a pharmaceutical composition, comprising the salt; a method of treating cancer, benign prostatic hyperplasia (BPH), and/or Kennedy's disease in a subject, comprising administering the salt to the subject; a method of prolonging survival of a subject having cancer, comprising administering the salt to the subject; a method of inducing androgen receptor (AR) degradation in a subject comprising administering the salt to the subject; and a method of inducing Mnk1/2 transcriptional activity degradation in a subject, comprising administering the salt to the subject.
C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Plasmodium falciparumPlasmodium malariaePlasmodium vivax,Plasmodium ovalePlasmodium knowlesiPlasmodium knowlesi in regions endemic for malaria. Also provided are immunogenic compositions, vaccines and multi-epitope vaccines constructed from the identified antigenic epitopes and methods for treating malaria in a subject, blocking transmission of malaria in a subject and initiating immune responses against Pf merozoite Rh5 interacting protein (PfRipr) and to inhibit erythrocyte invasion.
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
The present invention relates to the use of hypoxia-inducible factor (HIF) inhibitors in cancer immunotherapy. Specifically, the disclosure provides methods of treating a cancer in a subject in need of cancer immunotherapy, comprising administering a HIF-1a inhibitor to the subject and a second cancer immunotherapeutic agent to the subject, wherein the HIF-1a inhibitor comprising echinomycin, and wherein the second cancer immunotherapeutic agent comprising an anti-CTLA-4 antibody including Ipilimumab or Tremelimumab.
CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS
Mcl-1 selective inhibitors, Bcl-2 selective inhibitors, and Mcl-1/Bcl-2 dual inhibitors and methods of using the same for the treatment of disease are disclosed.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 235/24 - Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
46.
COMPOSITIONS AND METHODS FOR TARGETING A SPLICE VARIANT OF THE REGULATORY SUBUNIT OF MYOSIN PHOSPHATASE (MP) FOR THERAPEUTIC GAIN IN HYPERTENSION AND HEART FAILURE
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Fisher, Steven, Andrew
Abstract
The present invention provides an oligomer capable of binding to a target site of precursor messenger RNA (pre-mRNA) of myosin phosphatase target subunit (Mypt1) in cells, wherein binding of the oligomer to the target site of the pre-mRNA suppresses splicing of exon 24 of myosin phosphatase target subunit (Mypt1) in cells. Pharmaceutical compositions comprising the same and methods of use thereof are further provided.
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Compounds and methods of using the same for treating conditions alleviated by SKI complex inhibition, viral replication inhibition, or interferon signaling inducement are provided.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 239/40 - One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides a non-viral polyplex particle for delivering nucleic acid to cells, comprising an effective amount of polyethylenimine complexed with an effective amount of the nucleic acid; and an effective amount of an anionic biomaterial that envelops the complexed acetylated polyethylenimine and nucleic acid.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
49.
METHODS OF TREATING EYE DISEASES USING OPTIC NERVE LAMINA REGION NEURAL PROGENITOR CELL-DERIVED SECRETED EXTRACELLULAR VESICLES AND FREE PROTEINS
Soluble proteins and extracellular vesicles (EVs) produced by optic nerve lamina region neural progenitor cells (ONLR-NPCs) are provided. Such proteins and EVs include growth factors and survival factors that can be used in the treatment of optic nerve diseases, such as glaucoma. Also provided are methods of treating or preventing optic nerve diseases, such as glaucoma, using ONLR-NPC-based compositions.
A61F 9/00 - Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
50.
ENGINEERED FLAVIVIRUS ENVELOPE GLYCOPROTEIN IMMUNOGENIC COMPOSITIONS AND METHODS OF USE
The present invention provides polypeptides, and polypeptide dimers, comprising a modified flavivirus envelope E polypeptide, wherein the modified flavivirus envelope E polypeptide comprises i) a cysteine residue in a fusion loop epitope of ectodomain DII; and ii) a cysteine residue in ectodomain DI located in an N-terminal portion of the polypeptide, nucleic acids, vectors, host cells, and pharmaceutical compositions comprising the same, and methods of inducing an immune response in subjects by administering the pharmaceutical compositions of the invention.
A method and apparatus for monitoring collection of subject condition data is provided. The method includes receiving a value of a parameter of subject condition data and a value of a sample time, for each of a plurality of sample times. The method also includes storing the subject condition data in a data structure including a first field for holding data indicating a current sample time and a second field for holding data indicating the value of the parameter. The method also includes determining a time gap defined by a duration between the current sample time and a most recent sample time and determining whether the time gap exceeds a time gap threshold and causing an apparatus to perform remedial action. A method for presenting the subject condition data on a display is also provided.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
52.
METHODS FOR ASSAYING SLC34A2 EXPRESSION IN MUSCLE TISSUE AND TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
The present invention is directed to methods of detecting SLC34A2 expression in muscle tissue in a sample from a subject comprising providing the sample from the subject; and conducting an assay to detect an expression level of SLC34A2 in the sample.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described herein are methods and apparatus for approximating targeted tissue using locking sutures. The locking sutures can be configured to receive suture ends that are interweaved through portions of the locking sutures. In a pre-deployment configuration, a locking suture can slide along suture tails and can be positioned at a target location within a target region. Once a desired position and/or tension is achieved, the locking suture can be transitioned to a post-deployment configuration where the locking suture constricts around the suture tails to inhibit relative movement between the suture tails and the locking suture. A visualization system can be used to provide visual feedback with respect to approximating the targeted tissue and the locking sutures.
A61B 17/04 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for suturing wounds; Holders or packages for needles or suture materials
54.
METHOD AND APPARATUS FOR AUTOMATING MODELS FOR INDIVIDUALIZED ADMINISTRATION OF MEDICAMENTS
Techniques for generating a dosing protocol for an individual include receiving first data that indicates, for a dose response to a medicament, a non-linear mixed effects (NLME) model of a population with at least one distribution parameter characterizing variations in the population based on an observable property of individuals within the population. At least one of a structural model or a dynamical model of the NLME model is based on training weights of a universal approximator on a least a subset of the population. A candidate dose regimen is evaluated for an expected response by a subject based on the NLME model and one or more properties of the subject. When the expected response is therapeutic, the candidate dose regime of the medicament is administered to the subject.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
55.
LIVE SALMONELLA TYPHI VECTORS ENGINEERED TO EXPRESS CANCER PROTEIN ANTIGENS AND METHODS OF USE THEREOF
SalmonellaSalmonellaSalmonellaSalmonella Typhi vector is capable of delivering the antigen to a mucosal tissue or subcutaneously to dendritic cells via an outer membrane vesicle when administered to a subject.
The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.
Methods for treating and/or preventing Alzheimer's disease via administration of thioredoxin-1 (Trxl) mRNA- or miR-55lb miRNA-containing exosomes derived from Flk-1+ vascular endothelial progenitor cells are reported. Further, wherein the subject carries the APOE E4 risk factor gene; wherein the subject also has mild cognitive impairment (MCI); and wherein the Flk-1 + exosomes are derived from vascular endothelial progenitor cells or the exosomes are derived from neural stem cells.
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
58.
ANTI-PD-L1 MULTIPARATOPIC ANTIBODY CONSTRUCTS AND USES THEREOF
Provided herein are anti-PD-L1 multiparatopic antibody constructs that include a plurality of antigen-binding fragments, wherein a first antigen-binding fragment of the plurality of antigen-binding fragments binds specifically to a first PD-L1 epitope, and wherein a second antigen-binding fragment of the plurality of antigen-binding fragments binds specifically to a second PD-L1 epitope.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
An oxygen supply unit for use with a blood oxygenator comprises an oxygen concentrator and a carbon dioxide scrubber. In an on-line operational mode, oxygen-rich gas from the oxygen concentrator is predominantly supplied to the blood oxygenator with a reduced flow of recycled gas from the concentrator. In an off-line operational mode where the oxygen supply unit is being powered by battery only, a larger flow of recycled gas from the blood oxygenator is passed through the carbon dioxide scrubber and combined with a lesser amount of oxygen-rich gas from the oxygen concentrator. The oxygen supply unit may be used in combination with a blood pump and oxygenator to provide ambulatory blood oxygenation to patients with compromised lung function.
Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A01K 67/00 - Rearing or breeding animals, not otherwise provided for; New breeds of animals
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
61.
DEVELOPMENT OF CARBOHYDRATE-BASED ANTI-SALMONELLA VACCINES
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A plurality of heterogeneous microparticles can be provided, each having a shell, a payload, and a cap. The shell can define a core and an orifice in fluid communication with the core. The payload can be disposed within the core. The cap can be coupled to the shell so as to seal the orifice. The shell and cap of the microparticles can be formed by an additive manufacturing method, for example, by patterning of photomaterials using electromagnetic radiation or a particle beam. When subjected to a triggering event, at least a portion of each orifice can be exposed from the respective cap so as to release, through the exposed orifice portion, the corresponding payload from the core of the shell. The microparticles can be used in various applications, such as controlled delivery of drugs, chemicals, or biological agents, self-healing or self-lubricating materials, and failure prevention or mitigation.
Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.
C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Provided herein are methods for treating brain cancers, such as malignant gliomas, particularly glioblastomas. Inhibitors of dihydroorotate dehydrogenase singly or in combination with at least other one small molecule drug acting synergistically with the dihydroorotate dehydrogenase inhibitor are administered to a subject with a brain cancer or brought into contact with brain cancer tumor cells. Administration of a drug regimen of the inhibitor and at least one of the small molecule drugs increases sensitivity of a malignant glioma thereto.
Methods for non-invasively identifying substandard or counterfeit products, e.g., vaccines, using nuclear magnetic resonance. The methods provide manufacturers with new approaches to identify parameters to assist users with the identification of substandard or counterfeit products.
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
G01N 15/04 - Investigating sedimentation of particle suspensions
The present invention relates to angle-tuned (AT) ring coil devices to reduce the individual coil footprint and improve depth-spread characteristics of transcranial magnetic stimulation (TMS) systems. The AT coil device includes multiple stacked coils, which enhances field strength, reduces the footprint, and increases the field penetration depth by modifying its geometric distribution. Moreover, the AT coil devices demonstrated superior performance for multisite stimulation due to their smaller footprint, making them suitable for multisite stimulations of inter and intra-hemispheric brain regions with an improved spread and less electric field divergence.
Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 14/21 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
The present disclosure relates to electrochemical biosensing systems and methods that can be adapted to accurately and rapidly detect a target gene in clinical samples, using anti-sense oligonucleotides for selective detection of biological pathogens.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
The present invention relates to compositions and methods for identifying and treating signature MP-associated diseases and conditions in subjects. In particular, treatment methods of the invention include administering a gelsolin agent to produce a therapeutic effect against a signature MP-associated disease or condition in a subject.
Substituted chromen-2-one compounds, synthesized using computer-aided virtual screening in combination with structure-based drug design (SBDD), for inhibiting the enzymatic activity of alcohol dehydrogenase-2 (ALDH2) and liver-specific OATP1-dependent uptake, pharmaceutical compositions thereof, and methods of using the same for the treatment of alcohol use disorders (AUDs) are disclosed. In some embodiments, the inventive compounds inhibit liver-specific ALDH2 protein.
C07D 215/02 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
C07D 215/28 - Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
C07D 311/26 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
This invention relates generally to injectable drug delivery systems and methods of preparing same, and in particular to drug delivery systems comprising biodegradable polymeric nanogel formulations that form a depot (gel) in the body once injected, and can release therapeutic agents with enhanced extended-release times in the subject being treated. The polymer matrix drug delivery systems of the subject invention are comprised of a biodegradable polymer, a solvent or a combination of solvents, an alkylphenol, and therapeutic agents such as insulin, tetrandrine, other small molecule drugs (preferably hydrophobic drugs) to treat a variety of diseases including diabetes and hearing loss. A preferred alkylphenol is meta cresol which has demonstrated importance for dissolving and stabilizing the therapeutic agents, and forming gels with better shape and controlled drug release after injection.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
75.
PLATFORM NANOPARTICLE TECHNOLOGY FOR SUSTAINED DELIVERY OF HYDROPHOBIC DRUGS
This invention relates to a nanogel platform technology that can increase the water solubility of hydrophobic compounds, particularly hydrophobic compounds having one or more double bonds, by more than about 400 fold. Methods according to embodiments of the invention involve copolymerizing the hydrophobic compound with N-isopropylacrylamide monomer and dextran-lactate-2-hydroxyethyl-methacrylate macromer via UV emulsion polymerization in aqueous solution. The resulting nanosystem has the additional advantage of being able to sustain the release of the drug candidate for a long period of time, thus increasing the half-life, long-term bioavailability and therapeutic effects of these hydrophobic compounds.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
76.
NANOGEL PLATFORM TECHNOLOGY FOR LONG-TERM BIOLOGICS THERAPY
Biologics, including peptides, proteins, antibodies, nucleic acids (DNA and RNA), oligonucleotides, vaccines, or complex combinations of these substances, are important for treating various types of diseases and tissue and organ regeneration. However, biologics are not stable and have short half-lives, making effective delivery to patients difficult. Therefore, there is an unmet need in the art to increase the stability and half-lives of biologics for long-term bioavailability, therapy, treatment and repair. This invention provides a nanogel platform technology that can load biologics in aqueous solution with high loading efficiency without using any organic solvent and also sustain the release of active biologics in the body for more than 2 months.
Deposition of calcium-containing minerals such as hydroxyapatite and whitlockite in the subretinal pigment epithelial (sub-RPE) space is linked to the development of, and progression to, end-stage age-related macular degeneration (AMD). Calcification in the sub-RPE space is also directly linked to other diseases such as Pseudoxanthoma elasticum (PXE). These deposits bind to tetracycline derivatives and can be imaged by fluorescence lifetime contrast using multiphoton (infrared) excitation.
Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.
Here, we describe an infant with congenital dilated cardiomyopathy (cDCM) whose impaired cardiac function and disrupted sarcomere and mitochondria structures were modeled using induced pluripotent stem cells (iPSCs). The causal gene encodes the centrosomal protein rotatin (RTTN), representing the first time a centrosome defect has been found to cause nonsyndromic dilated cardiomyopathy (DCM) in humans. Genetic knockdowns in zebrafish and Drosophila confirmed an evolutionarily conserved requirement of RTTN for cardiac structure and function. The small molecule, C19, restored initiation of the perinuclear MTOC, and significantly improved the structure and function of cardiomyocytes. In summary, this study provides a new therapeutic strategy for infantile or congenital DCM
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 9/00 - Drugs for disorders of the cardiovascular system
80.
MUTANT CD24 PROTEINS AND USES THEREOF FOR PROPHYLAXIS AND TREATMENT OF CANCER
Provided herein are mutant CD24 proteins, RNAs, compositions thereof, and the use of the proteins and compositions in cancer therapy and as vaccines for cancer prophylaxis.
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (USA)
THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY (USA)
UNIVERSITY OF MARYLAND, BALTIMORE (USA)
Inventor
Joyce, Michael Gordon
Modjarrad, Kayvon
Dooley, Helen
Hajduczki, Agnes
Chen, Wei-Hung
Abstract
Disclosed herein are shark-derived antibodies and binding molecules with high binding affinity for SARS-CoV-2 coronavirus and the use thereof. Some of the shark-derived antibodies and binding molecules also demonstrate cross-reactivity with and neutralization of other related sarbecoviruses. The complementarity determining region (CDR) sequences and binding characteristics for these antibodies and binding molecules are provided. Also disclosed are the use of these antibodies and binding molecules to detect SARS-CoV-2 coronavirus or other related sarbecoviruses or to prevent or treat SARS-CoV-2 coronavirus or other related sarbecovirus infections.
A method and apparatus for testing balance of a subject is provided. The apparatus includes a plurality of modules detachably coupled together to form a walkway. Each module includes an obstacle. The obstacle of one of the modules is a movable obstacle configured to move from a first position to a second position. The obstacle of one of the modules is a fixed obstacle in a fixed position. A system is also provided that includes the apparatus of the first set of embodiments. The system also includes a sensor configured to measure a value of a parameter indicating a characteristic of motion of a subject over the walkway. A method is also provided that includes detachably coupling the plurality of modules together to form the walkway. The method further includes measuring the parameter value indicating the response of the subject to each obstacle of each module along the walkway.
The present disclosure unravels novel mechanistic information involving the direct regulation of OBSCN via OBSCN-AS1 through chromatin remodeling and enhanced RNA polymerase II recruitment. Remarkably, it is shown herein that targeting of OBSCN-AS1 is sufficient to restore OBSCN expression in highly aggressive triple-negative breast cancer cells. Provided herein are methods for increasing OBSCN expression in a cell, comprising providing to the cell one or more agents that increases levels of OBSCN-AS1 IncRNA or a variant thereof in the cell, and CRISPR/Cas9 systems for increasing levels of OBSCN-AS1 IncRNA in cells.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
84.
METHODS OF TREATING CANCER BY INHIBITING BACTERIAL DNAK TO RESTORE ACTIVITIES OF ANTICANCER DRUGS
The present invention provides a method for increasing the efficacy of an anticancer therapy by administering to a subject in need thereof at least one compound that at least partially blocks the activity of a bacterial DnaK, and pharmaceutical compositions comprising the same.
C07K 14/30 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms (PPLO)
The present invention relates to the use of a condensate collector such as portable or stationary dehumidifier placed in a defined testing space or area and used as a readily available and affordable tool to collect airborne virus particles in collected condensate from the testing atmosphere in the defined testing space or area, wherein the collected condensate is analyzed for virus biomarkers to identify viruses, such as SARS-CoV-2 or mutants or variants thereof, in the testing atmosphere.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
Provided herein are dual vector systems for expressing a Protocadherin-15 protein or variant thereof in a subject, wherein the dual vector system comprises a first vector comprising a first coding polynucleotide that encodes an N-terminal portion of the Protocadherin-15 protein or variant thereof; and a second vector comprising a second coding polynucleotide that encodes a C-terminal portion of the Protocadherin-15 protein or variant thereof, wherein the first coding polynucleotide and the second coding polynucleotide that encode the Protocadherin-15 protein or variant thereof do not overlap.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Dural repair devices that are configured to effectively and reliably repair the damage of a dural tear due to incidental durotomies are provided, along with methods of use. The devices and methods enhance the ability of a surgeon to repair a patent's dura mater, or dura, during surgery of the central nervous system. The dural repair device has a multi-layer structure configured to exert a pressure or tamponade effect to compress a patient's dura to its state prior to the spinal surgery. Thus, the dural repair devices and methods of use may reduce the patient's risk morbidity, further surgery, spinal headaches, or other injuries and discomforts.
A61F 2/44 - Joints for the spine, e.g. vertebrae, spinal discs
A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 31/14 - Materials characterised by their function or physical properties
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.
C07D 295/03 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
89.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Simard, J., Marc
Gerzanich, Vladimir
Stokum, Jesse
Abstract
The present invention provides methods for treating reperfusion edema in patients who have suffered a stroke, the methods comprising administering an effective amount of one or more inhibitors of sodium D-glucose cotransporter 2 (SGLT2). The invention further contemplates administration of SGLT2 inhibitors in combination with recombinant tissue plasminogen activator (rtPA). Exemplary SGLT2 inhibitors include canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin etabonate, sergliflozin etabonate, sotagliflozin, tofogliflozin and combinations thereof.
Compositions and methods for improved delivery of mRNA into eukaryotic cells using histidine-lysine (HK) peptide polymers are disclosed. The branched polymers comprising four short peptide branches linked to a three-lysine amino acid core. The peptide branches consist of histidine and lysine amino acids, in different configurations, and they can vary in their location on the lysine core.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Atamas, Sergei P.
Luzina, Irina G.
Abstract
The present invention provides an IL-33 decoy peptide comprising an amino acid sequence of a fragment of FLIL33 or a fragment of a FLIL33 variant, wherein the decoy peptide disrupts an association of FLIL33 with an FLIL33 binding partner.
Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
An implantable device for sacroiliac (“SI”) joint fusion and an associated method employ an SI joint fusion portion and an anchor portion of smaller diameter than the SI joint fusion portion and that extends distally from a distal end of the SI joint fusion portion. The SI joint fusion portion is externally threaded and is configured to, when surgically implanted, extend across the SI joint. The anchor portion in turn extends distally from the SI joint fusion portion and is configured for implanting entirely within the patient’s ilium adjacent the SI joint. In certain configurations, the joint fusion portion is configured to enable fixation of spinal equipment at a proximal end of the joint fusion portion.
A system for and method of autonomously robotically acquiring an ultrasound image of an organ within a bony obstruction of a patient is presented. The techniques include acquiring an electronic three-dimensional patient-specific representation of the bony obstruction of the patient; obtaining an electronic representation of a target location in or on the organ within the bony obstruction of the patient; determining, automatically, position and orientation of an ultrasound probe to acquire an image of the target location; and directing, autonomously, and by a robot, the ultrasound probe on the patient to acquire the image of the target location based on the position and orientation.
The present disclosure relates to novel deuterated retinoidal compounds and methods of preparing the deuterated retinoidal compounds. The present disclosure also provides pharmaceutical compositions including the deuterated retinoidal compounds, and uses of the deuterated retinoidal compounds to treat diseases including breast and prostate cancers.
The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector, wherein the Salmonella Typhi vector has been engineered to express one or more cancer antigens. In some aspects the vector has been engineered to express an outer membrane folding protein BamA or a fragment or variant thereof; and a lipid A deacylase PagL or a fragment or variant thereof, wherein the Salmonella Typhi vector is capable of delivering the antigen to a mucosal tissue or subcutaneously to dendritic cells via an outer membrane vesicle when administered to a subject.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Birukov, Konstantin
Eggerman, Thomas L.
Bocharov, Alexander V.
Renn, Cynthia L.
Abstract
Therapeutic agents, compositions, and methods are described for use in the treatment of acute or chronic pain, neuroinflammation, or conditions characterized by acute or chronic pain or neuroinflammation. The therapeutic agents comprise a synthetic amphipathic helical peptide capable of acting as a mimetic of apoA-I protein.
Provided herein are bioresorbable, bioregenerative composite materials and compositions to regenerate tissues or organs to repair tissue or organ defects and constructs printed from the same as 3D structures shaped and sized to fill a tissue or organ defect. The composite materials are bioresorbable polymers, for example, polycaprolactone, and a bioresorbable graft material, for example, demineralized bone matrix. Also provided are methods for making the composite materials and compositions and methods for regenerating tissues or organs and repairing a tissue or organ defect using the constructs.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventor
Lin, Jiayuh
Pan, Li
Li, Chenglong
Abstract
Methods of using the small molecule STAT3 inhibitor LLL12B in the treatment of cancer, such as triple-negative breast cancer (TNBC) and pancreatic cancer, either alone or in combination with additional therapeutic agents, such as PARP inhibitors and CDK inhibitors, are provided.
C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
